NASH

Successful phase II trial of FGF19 analogue

Evidence has suggested a role for excess bile acids in the pathogenesis of non-alcoholic steatohepatitis (NASH). Fibroblast growth factor 19 (FGF19), a hormone regulating bile acid metabolism, might have therapeutic potential in treating NASH, but studies have been hindered by its hepatocarcinogenicity. Now, a non-tumorigenic variant of FGF19, NGM282, has been assessed in a placebo-controlled phase II trial in 82 patients with NASH. Patients were randomly assigned to receive 3 mg (n = 27) or 6 mg (n = 28) of NGM282, or placebo (n = 27). After 12 weeks, MRI was used to show that 74–79% of patients in the NGM282 groups achieved at least a 5% reduction in absolute liver fat content from baseline, compared with 7% in the placebo group (P <0.0001 for both comparisons). Both doses of NGM282 were well tolerated.

References

  1. 1

    Harrison, S. A. et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 391, 1174–1185 (2018)

    CAS  Article  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dickson, I. Successful phase II trial of FGF19 analogue. Nat Rev Gastroenterol Hepatol 15, 256 (2018). https://doi.org/10.1038/nrgastro.2018.28

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing